TORONTO, ONTARIO / ACCESSWIRE / January 22, 2020 / CardioComm Solutions, Inc. (TSXV:EKG) ('CardioComm' or the 'Company'), a global medical provider of consumer heart monitoring and medical electrocardiogram ('ECG') software solutions, announced the proposed issuance of shares and the issuance of stock options.
Under shares for debt agreements, the Company will issue an aggregate of 650,000 common shares of the Company ('Shares') to directors of the Company at a deemed price of $0.05 per Share. The Shares will be provided to settle debt for service expenses and will be subject to a four month hold period in accordance with applicable securities laws. The Company also granted 62,500 stock options to a director of the Company, each option exercisable at $0.05 per Share for five years from the date of grant and vesting immediately. The options are subject to the provisions of the Company's Stock Option Plan, the policies of the TSX Venture Exchange and applicable securities laws.
The Company also announces the final tranche of shares to AGORA Internet Relations Corp. ('AGORACOM') in the amount of 226,000 Shares, representing a price of $0.05 per Share, for services valued at $10,000 plus 13% HST. AGORA is an online marketing and awareness company that will extend its support and coverage of CardioComm Solutions into the current calendar year, at no additional cost to the Company. Agoracom's market coverage will complement CardioComm's 2020 marketing campaign efforts for the HeartCheck™ CardiBeat and GEMS™ Mobile Smartphone app. The campaign will highlight the availability of rapid ECG reading services through the Company's SMART Monitoring ECG reading fee-for-service and connectivity readiness of this solution to hospitals where the Company's GEMS™ software is licensed.
To learn more about CardioComm's products and for further updates regarding HeartCheck™ ECG device integrations please visit the Company's websites at www.cardiocommsolutions.com and www.theheartcheck.com.
AGORACOM is the pioneer of online investor relations, online conferences and online marketing / branding services to North American small and mid-cap public companies, with more than 250 companies served. More than just lip service, AGORACOM is the home of more than 808K investors that visited 5.6 million times and read 52.4 million pages of information every year (Average 2008 - 2015).
AGORACOM traffic ranks within the top 0.5% of all websites around the world. These traffic results are independently tracked and verified by Google analytics. AGORACOM traffic can be attributed to its strategy of maintaining the cleanest, moderated small-cap discussion as a result of implementing the first ever Investor Controlled Stock Discussion Forums.
AGORACOM Founder, George Tsiolis, publishes the leading blog on small & mid cap investor relations. His 50 Small-Cap CEO Lessons are a must read for CEO's looking to increase their education and knowledge about online investor relations.
About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada).
FOR FURTHER INFORMATION PLEASE CONTACT:
This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: CardioComm Solutions, Inc
View source version on accesswire.com: